Tango Therapeutics (TNGX) Total Current Liabilities (2020 - 2026)

Tango Therapeutics' Total Current Liabilities history runs 7 years deep, the most recent figure standing at $14.3 million for Q1 2026.

• In Q1 2026, Total Current Liabilities fell 60.1% year-over-year to $14.3 million; the TTM figure through Mar 2026 stood at $14.3 million (down 60.1% YoY), while the FY2025 annual figure was $21.7 million, down 43.2% from the prior year.
• Total Current Liabilities was $14.3 million for Q1 2026 at Tango Therapeutics, down from $21.7 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $55.5 million in Q4 2022 to a low of $14.3 million in Q1 2026.
• Historically, Total Current Liabilities has averaged $40.0 million across 5 years, with a median of $42.8 million in 2024.
• The sharpest annual moves came in 2022 and 2026: Total Current Liabilities soared 12885.32% in 2022, then slumped 60.1% in 2026.
• A 5-year view of Total Current Liabilities shows it stood at $55.5 million in 2022, then declined by 17.3% to $45.9 million in 2023, then declined by 16.91% to $38.2 million in 2024, then plunged by 43.2% to $21.7 million in 2025, then sank by 33.9% to $14.3 million in 2026.
• The last three Total Current Liabilities figures came in at $14.3 million (Q1 2026), $21.7 million (Q4 2025), and $18.4 million (Q3 2025), per Business Quant data.